Mirabegron, a First-in-class Non-antimuscarinic Drug for the Overactive Bladder | Chapter 4 | Novel Research Aspects in Medicine and Medical Science Vol. 8

 Background: Overactive pouch (OAB) treatment filed a new era with the inauguration of mirabegron. Its favorable productiveness-tolerability profile has happened demonstrated in multiple randomized, international, controlled troubles, both short- and enduring.Objectives: To investigate through a literature review the potential duty of mirabegron in the first-line treatment of OAB and the potential function of the b3-agonism in the treatment of additional urological-related pathologies.Results: The favorable productiveness-tolerability profile concerning this first-in-class, potent b3-adrenoceptors agonist has happened demonstrated in multiple randomized regulated trials, two together short- and long-term. The cardiovascular safety of mirabegron situation has been stated with solid consistency throughout studies. Mirabegron displayed a placebo-like occurrence of classic adverse belongings caused by antimuscarinics. Patients with antimuscarinic contraindications and those the one have discontinued earlier antimuscarinic therapy can use mirabegron.Conclusion: A new class of compounds, with a novel mechanism of operation, is available in the pharmacological arsenal aimed to treat OAB. Several studies displayed the efficacy, safety, and tolerability sketch of this drug. Combination medicines represent a right therapeutic alternative to more invasive situation options in hard-to-treat subjects. Its use in specific states still needs to be clarified, but various studies are ongoing, testifying the expectation about the mirabegron.

Author(s) Details:

Filippo Marino,
Department of Urology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.

Francesco Rossi,
Department of Urology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.

Emilio Sacco,
Department of Urology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.

Please see the link here: https://stm.bookpi.org/NRAMMS-V8/article/view/12183